

Studies of Some Salicylidene Schiff Base Complexes of Aryltellurium

Savita Devi*

Department of Chemistry,
Maharshi Dayanand University, Rohtak-124001,
India.

savitalect@gmail.com

Abstract: A novel monobasic tridentate Schiff base Salicylidene-trimethoprim, Sal-TMP, synthesized from trimethoprim and salicylaldehyde, form stable complexes with aryltellurium(IV) trichlorides and diaryltellurium(IV) dichlorides of the type Sal-TMP.ArTeCl₂ and Sal-TMP.Ar₂TeCl (where Ar = *p*-methoxyphenyl, *p*-ethoxyphenyl, *p*-hydroxyphenyl and 3-methyl-4-hydroxyphenyl). These have been characterized by elemental analyses, molar conductance, IR and ¹H NMR spectroscopy. The spectral studies predict the bonding of ligand through phenolic oxygen of Schiff base after deprotonation, nitrogen of the azomethine group and pyrimidine nitrogen to give hexa-coordinated tellurium(IV) complexes. The complexes have also been screened for their antimicrobial activities against various bacteria and fungi organisms.

Keywords: Salicylidene-trimethoprim Schiff base, Aryltellurium(IV), Diaryltellurium(IV), Antibacterial and Antifungal activities.

Introduction

Trimethoprim and its derivatives are broad spectrum antimicrobial agents with anti-parasitic activity¹⁻⁶ and was

first described by Roth and coworker⁵.

Schiff bases, also known as azomethine due to presence of –C=N– group, play important role in

biological system, such as anticancer⁷⁻¹², antibacterial¹³⁻¹⁵, antiviral¹⁶⁻¹⁸, antifungal¹⁹⁻²¹ and other biological properties²²⁻²⁷ and also have been extensively used as ligands in coordination chemistry because of their excellent donor abilities as chelating agent²⁸⁻³². Medicinal chemists have reported new derivatives of Trimethoprim(TMZ)³³⁻³⁵ including the Schiff base derived from Salicylaldehyde^{2-4,36,37}.

Also, aryltellurium(IV) chlorides are known³⁸⁻⁵⁴ to act as Lewis acids and form complexes with several N-, O- and S- donor bases. In view of this, we herein report some new complexes derived from aryltellurium(IV) trichlorides, $R\text{TeCl}_3$ and diaryltellurium(IV) dichlorides, $R_2\text{TeCl}_2$ with Salicylidene-trimethoprim Schiff base(Sal-TMP).

Experimental

All preparations were carried out under an atmosphere of dry N_2 and the solvents used were purified by

standard method^{55,56} before use. The purity of compounds was checked by Thin Layer Chromatography using Silica gel-G (Merck). Melting points were determined in open capillary tube and are uncorrected.

Carbon, hydrogen and nitrogen analyses were obtained microanalytically from SAIF, Panjab University Chandigarh on a ThermoFinnigan CHNS analyser. Conductivity was measured in DMSO at 25 ± 2 °C with dip type conductivity cell on a microprocessor based conductivity bridge type MICROSIL.

IR(4000-400 cm^{-1}) and far IR(400-50 cm^{-1}) spectra were recorded in KBr/polyethylene pellets on a F.T. Infra-Red Spectrophotometer Model RZX (Perkin Elmer) at SAIF, Panjab University Chandigarh. Proton Magnetic Resonance Spectra were recorded in DMSO-d_6 using TMS as an internal reference on BRUKER AVANCE II 400 NMR spectrometer. The antimicrobial screening was carried out by Tube Dilution method

at Department of Pharmaceutical Sciences, M. D. University, Rohtak.

Preparation of Aryltellurium(IV) Trichlorides and Diaryltellurium(IV) Dichlorides

p-Methoxyphenyltellurium(IV) trichloride^{57,58}, bis(*p*-methoxyphenyl)tellurium(IV) dichloride^{58,59}, *p*-ethoxyphenyltellurium(IV) trichloride⁶⁰, bis(*p*-ethoxyphenyl)tellurium dichloride⁶⁰ *p*-hydroxyphenyltellurium(IV) trichloride⁶¹, bis(*p*-hydroxyphenyl)tellurium(IV) dichloride⁶¹, 3-methyl-4-hydroxyphenyltellurium(IV) trichloride⁶² and bis(3-methyl-4-hydroxyphenyl) tellurium(IV) dichloride⁶² were prepared by the reactions of TeCl₄ with anisole, phenetole, phenol, *o*-cresol respectively, by the methods reported in the literature⁵⁷⁻⁶².

Preparation of Salicylidene-trimethoprim Schiff Base (Sal-TMP)

Equimolar quantity of saturated methanolic solution of drug



and salicylaldehyde were mixed thoroughly. To this mixture 0.1% methanolic KOH was added to adjust the pH the solution between 7-8 and was refluxed for 2 hours. A clear yellowish- green coloured solution was obtained. After completion of the reaction, the Schiff base ligand was isolated by crystallization after volume reduction by evaporation. The crystalline product was filtered and dried under vacuum and kept in desiccator over P₄O₁₀ until further use. Yield = 80%, M.pt.(decomp.) = 188-190 °C. Analysis (Calculated) C₂₁H₂₂N₄O₄ : C(63.95), H(5.62) and N(14.20); Found: C(63.50), H(5.27) and N(13.99)

Preparation of Salicylidene-trimethoprim Complexes of Aryltellurium(IV) Trichlorides and Diaryltellurium(IV) Dichlorides

Aryltellurium(IV) trichlorides, ArTeCl₃ and diaryltellurium(IV) dichlorides Ar₂TeCl₂ (Ar = *p*-methoxyphenyl, *p*-ethoxyphenyl, *p*-hydroxyphenyl and 3-methyl-4-hydroxyphenyl), when reacted with

sodium salt of salicylidene-trimethoprim in equimolar ratio, yield Sal-TMP.ArTeCl₂ and Sal-TMP.Ar₂TeCl type complexes.

Sodium salt of the ligand was prepared by reacting equimolar (1:1) quantity of sodium metal and Schiff base in methanol. The solvent was distilled off to obtain sodium salt of Schiff base. Then a methanolic saturated solution of 2 mmol of aryltellurium(IV) trichloride or diaryltellurium(IV) dichloride was added dropwise to suspension of 2 mmol of sodium salt of Schiff base in about 50 mL benzene under reflux. The reaction mixture was further refluxed for 3-4 hours, cooled and precipitated sodium chloride was filtered off. The filtrate was then concentrated to about one third of




Preparation of Salicylidene-trimethoprim Schiff base (Sal-TMP) by the reaction of trimethoprim drug and salicylaldehyde can be represented by following equations.



original volume under reduced pressure and cooled in an ice bath to obtain coloured product. This was filtered, washed with benzene + methanol (1:1) and dried in vacuum desiccator over P₄O₁₀.

Results and Discussion

TeCl₄ when heated with anisole⁵⁷⁻⁵⁹, phenetole⁶⁰, phenol⁶¹, *o*-cresol⁶² (Ar-H) appears to undergo Friedel-Crafts type condensation reaction whereby TeCl₃⁺ unit attacks a position *para* to the methoxy/ethoxy/hydroxy groups in the aromatic rings, thus resulting in the formation of aryltellurium(IV) trichlorides and diaryltellurium(IV) dichlorides.



Sodium salt of Salicylidene-trimethoprim Schiff base (Sal-TMP) reacts with aryltellurium (IV) trichlorides and diaryltellurium(IV) dichlorides in 1:1 molar ratio to yield the corresponding aryltellurium(IV) complexes.



All the tellurium(IV) complexes are coloured, crystalline solids, stable at room temperature and non-hygroscopic in nature. The complexes have been analysed for their tellurium, chlorine, carbon, hydrogen and nitrogen contents and the data along with their physical properties and yields.

Conductance Studies

The Λ_M value at *ca.* 10^{-3} M for aryltellurium(IV) complexes in DMSO lie in the range 27.36-91.83 $\text{S cm}^2 \text{mol}^{-1}$ which predict


the non electrolyte to 1:1 electrolyte^{63,64} type behaviour of these complexes in DMSO, probably due to ionization into $\text{ArTeCl}.\text{Sal-TMP}^+/\text{Ar}_2\text{Te}.\text{Sal-TMP}^+$ and Cl^- in DMSO. This conductance behaviour of tellurium (IV) salicylidene-trimethoprim Schiff base complexes is different from those of transition metal complexes⁶⁵, which are reported to be non-electrolytes. The higher Λ_M values for some complexes may be due to steric factors and donor behaviour of DMSO to result in probable

dissociation into solvated cation and L^- along with Cl^- in DMSO.

Infrared Spectra

The spectra of Sal- TMP Schiff base complexes are quite complex and an attempt has therefore been made to identify the donor sites by comparing the spectra of complexes with parent ligand and $ArTeCl_3/Ar_2TeCl_2$.

Examination of the Schiff Base (Sal-TMP) spectrum shows the presence of the hydrogen bonded conjugated- chelate ring system⁶⁶⁻⁶⁸ with its centre at $\sim 2832\text{ cm}^{-1}$. Thus intramolecular H-bonding is occurring by means of the formation of a quasi six-membered ring involving the OH - ---N=C bond.



Hydrogen bonding

Thus band disappear on chelation with aryltellurium(IV) chlorides⁶⁹. Hydrogen bond contributes to planarity of the molecule which help in chelation⁷⁰. Also an intense ligand band at 1263 cm^{-1} (phenolic -C-O) in free ligand has shifted to higher frequency side in complexes. All these indicate that the hydroxyl group of salicylaldehyde of Schiff base is involved in coordination with tellurium⁷¹⁻⁷³.

In addition, the spectra of the Schiff base shown shoulder at 1636 cm^{-1} with slightly resolved weak band at 1633 cm^{-1} and sharp band at 1593 cm^{-1} assigned to $\nu_{(C=N)}$ mode for vibration of azomethine group^{2,4,65,74-76} and

$\nu_{(C=N)pyrim.}$ for pyrimidine ring^{4,77}. These shift in aryltellurium Schiff base complexes towards higher and lower value⁷⁴⁻⁷⁹ reflecting that ligand coordinate through nitrogen atom of azomethine and pyrimidine ring.

The medium intensity band at 3317 cm^{-1} and 3119 cm^{-1} due to $\nu_{(N-H)}$ asymmetric and symmetric vibrations respectively indicate the non involvement of the nitrogen atom of NH_2 group attached to pyrimidine in coordination. The appearance of new weak bands around $270\text{-}295\text{ cm}^{-1}$ due to $\nu_{(Te-O)}$ ⁸⁰⁻⁸³ mode and medium to strong band in the range of $410\text{-}422\text{ cm}^{-1}$ due to $\nu_{(Te-N)}$ mode⁸⁴ further supports the involvement of phenolic oxygen (after deprotonation), azomethine and pyrimidine nitrogen atoms of Schiff base in the coordination.

Thus, IR data predict the tridentate nature of Sal-TMP

involving azomethine nitrogen atom, phenolic oxygen after deprotonation and pyrimidine ring nitrogen giving rise to two-six and four membered chelate rings with the tellurium centre.


¹H NMR Spectra

The proton resonance of the OH group at $10.92\text{ }\delta\text{ ppm}$ ^{76,85} in Schiff base due to presence of intramolecular hydrogen bonding⁷⁴ disappear on complexation indicating the involvement of phenolic oxygen in the coordination *via* deprotonation⁷⁶. The azomethine protons which resonate as a singlet at $10.02\text{ }\delta\text{ ppm}$, the coordination of azomethine nitrogen to tellurium in the complexes is clearly demonstrated by a downfield shift of the peak⁸⁶.


The characteristic downfield shifting of proton signal in all complexes observed in

region 5.67 δ ppm is due to pyrimidine proton in Schiff base clearly indicate the coordination through pyrimidine nitrogen atom⁸⁷. The signal due to $-NH$ proton is observed around 6.51 δ ppm which remain intact with slight variation in complexes is due to the proton bounded to nitrogen experience quadruple effect⁸⁷. Thus salicylidene-

trimethoprim act as a tridentate $-N, -N, -O$ chelating ligand in $Sal-TMP.ArTeCl_2$ and $Sal-TMP.Ar_2TeCl$ complexes giving six coordinate tellurium having distorted octahedral geometry in these complexes as predicated from IR studies as well. The proposed structures are as below (Figure 1):



Sal-TMP.ArTeCl₂



Sal-TMP.Ar₂TeCl

Ar = *p*-methoxyphenyl, *p*-ethoxyphenyl, *p*-hydroxyphenyl and 3-methyl-4-hydroxyphenyl

Figure 1. Proposed Structures of Complexes

Biological Activity

The salicylidene-trimethoprim Schiff base (Sal-TMP) and newly synthesized aryltellurium(IV) schiff base complexes were evaluated for their antimicrobial activity *in vitro* against Gram +ve bacteria (*S. aureus* ATCC 11632 and *B. cereus* MTCC 7350), Gram -ve bacteria (*E. coli* ATCC 35218, *P. aeruginosa* ATCC 23564, *S. typhi* ATCC 15499 and *P. rettgeri* DRDE) and fungal strains (*A. niger*, *A. fumigates* and *A. flavus*)

by tube dilution method⁸⁸. Dilution of test and standard compounds were prepared double strength nutrient broth- I.P (Antibacterial) and Sabouraud Dextrose Broth –I.P (Antifungal)⁸⁹. The samples were incubated at 37±1°C for 24h (bacteria), 25±1°C for 7 days (*A. niger*), 30 ±1°C for 15 days (*A. flavus*), 35±1°C for 72hrs (*A. fumigates*) respectively and results were recorded in terms of MIC (The lowest concentration of test substances which inhibited values are presented in the Table 4.

Table 4: Minimum Inhibitory Concentration, MIC (µg/mL); (-) Resistant.

Compound	Bacteria strains						Fungal strains		
	<i>S. aureus</i> (ATCC 11632)	<i>S. typhi</i> (ATCC 15499)	<i>P. aeruginosa</i> (ATCC 23564)	<i>E. coli</i> (ATCC 35218)	<i>B. cereus</i> (MTCC 7350)	<i>P. rettgeri</i> (DRDE strain)	<i>A. niger</i>	<i>A. fumigates</i>	<i>A. flavus</i>
Sal-TMP	2.5	-	1.25	5.0	-	-	20	5.0	1.25
I	2.5	-	1.25	-	0.625	5.0	-	-	-
II	5.0	-	-	-	1.25	2.5	20	5.0	1.25
III	-	20	10	5.0	1.25	-	5.0	-	-
IV	1.25	2.5	1.25	5.0	-	-	5.0	10	5.0
V	-	20	10	5.0	1.25	-	20	-	-
VI	1.25	2.5	1.25	5.0	-	-	-	5.0	-
VII	1.25	-	5.0	1.25	0.625	5.0	-	10	-
VIII	2.5	-	1.25	5.0	-	-	20	5.0	1.25

The data show that the Sal-TMP complexes of aryltellurium(IV) exhibit more antimicrobial activity towards bacteria as compared to fungi. The antibacterial activity shows following trend:

Sal-TMP.Ar₂TeCl > Sal-TMP.ArTeCl₂ ≈ Sal-TMP Schiff base

Aryltellurium (IV) and diaryltellurium(IV) dichlorides upon reaction with Schiff base(Sal-TMP) derived from salicylaldehyde and trimethoprim yield new complexes of tellurium(IV). The synthesized complexes were characterized by elemental analyses, conductance measurement, IR and ¹H NMR spectral studies. The analytical data suggest that the Sal-TMP Schiff base complexes have 1:1 stoichiometry. The Schiff base (Sal-TMP) in these complexes functions as a uninegative tridentate ligand through azomethine

Sal-TMP.Ar₂TeCl and Sal-TMP.ArTeCl₂ complexes have activity towards *S. typhi* and more effectively against *B. cereus* but Schiff base does not show activity against these bacterial strains. Schiff base and its complexes show almost similar activity against fungal strains.

Conclusion

nitrogen, phenolic oxygen after deprotonation and pyrimidine ring nitrogen atoms. Based on these studies, distorted octahedral geometry with two chelating rings has been assigned to these complexes. The complexes have been observed to possess substantial antimicrobial activity especially against bacteria.

References

1. Burchall J J, Corcoran J W and Hahn F E, *Eds. Antibiotics*,

- Springer, New York, NY, USA, 1975, **3**.
- Iqbal M S, Khan A H, Loothar B A and Bukhari I H, *Med. Chem. Rev.*, 2009, **18**, 31-42.
 - Blower P J, *Annu. Rep. Prog. Chem. Sect. A*, 1999, **95**, 631-655.
 - Dhahir S A, Al-Sahib S A, Al Razaq W A and Kadhim N J, *Baghdad Science Journal*, 2010, **7(1)**, 621.
 - Dr. Karl Thomae GmbH(Biberach an der Riss. DE), United States Patent. 4829058.
 - Al-Noor T H and Karim A L K, *J. Chemistry and Material Research*, 2015, **7(5)**, 82-91.
 - Sinha D, Tiwari A K, Singh S, Shukla G, Mishra P, Chandra H and Mishra A K, *Eur. J. Med. Chem.*, 2008, **43(1)**, 160-165.
 - Crowe A J, Smith P J and Atassi G, *Chem. Biol, interact.*, 1980, **32**, 171-178.
 - Wang M, Wang L F, Li Y Z, Li Q X, Xu Z D and Qu D M, *Trans. Met. Chem.* 2001, **26**, 307-310.
 - Zishen Wu, Ziqi Gui and Zhenhuan Yen, *Synth. React. Inorg. Met. –Org. Chem.*, 1990, **20(3)**, 335-344.
 - Desai S B, Desai P B and Desai K R, *Hetrocycl. Commun.*, 2001, **7**, 83-90.
 - Dhumwad S D, Gudasi K B and Goudar T R, *Indian J. Chem.*, 1994, **33A**, 320-324.
 - Przybylski P, Huczynski A, Pyta K, Brzezinski B and Bartl F, *Curr. Org. Chem.*, 2009, **13**, 124-148.
 - Pandeya S N, Sriram D, Nath G and De Clercq E, *Pharm. Acta. Hely*, 1999, **74**, 7-11.
 - Karthikeyan M S, Parsad D J, Poojary B, Bhat K S, Holla B S and Kumari N S, *Bioorg. Med. Chem.*, 2006, **14**, 7482-7489.

16. Holla B S, Akberali P M and Shivananda M K, *II Farmaco*, 2001, **56**, 919-927.
17. Jarrahpour A, Khalili D, De Clercq E, Salmi C and Brunel J M, *Molecules*, 2007, **12**, 1720-1730.
18. Da Silva C M, da Silva D L, Modolo L V, Alves R B, de Resende, M A, Martins C V B and de Fatima A J, *Adv. Res.*, 2011, **2**, 1-8. doi:10.1016/j.jare.2010.05.004.
19. Singh H, Yadav L D S and Mishra S B S, *J. Inorg. Nucl. Chem.* 1981, **43**, 1701-1704.
20. Saravanan G, Pannerselvam P and Prakash C R, *J. Adv. Pharm. Techn. Res.*, 2010, **1**, 320-325.
21. Panneerselvam P, Nair R R, Vijayalakshmi G, Subramanian E H and Sridhar S K, *Eur. J. Med. Chem.* 2005, **40**, 225-229.
22. Singh N K and Singh S B, *Indian J. Chem.* 2001, **40A**, 1070-1075.
23. Walsh O M, Meegan M J, Prendergast R M, Nakib T A, *Eur. J. Med. Chem.*, 1996, **31**, 989-1000.
24. Odabasoglu M, Arslan F, Ölmez H and Büyükgüngör O, *Dyes and Pigments*, 2007, **75**, 507-515.
25. Vicini P, Geronikaki A, Incerti M, Busonera B, Poni G, Cabras C A and Colla P L, *Bioorg. Med. Chem.*, 2003, **11**, 4785-4789.
26. Pandeya S N, Sriram D, Nath G and DeClercq E, *Eur. J. Pharm. Sci.*, 1999, **9**, 25-31.
27. Samadhiya S and Halve A, *Orient. J. Chem.* 2001, **17**, 119-122.
28. Celik Ö, Ulusoy M, Tas E and Ide S, *Anal. Sciences*, 2007, **23**, x185.
29. Mahmoud M R, El-Gyar S A, Mousrafa A A and Shaker A, *Polyhedron*, 1987, **6**, 1017-1020.



30. Qing-Yu H, Zheng-Hua M and Ya-Me Z, *J. Coord. Chem.*, 1990, **21**, 199.
31. Cozzi P G, *Chem. Soc. Rev.*, 2004, **33**, 410-421.
32. Tarafder M T H, Jin KT, Crouse K A, Ali A M, Yamin, B M and Fun H K, *Polyhedron*, 2002, **21**, 2547-2554.
33. Pandeya S N, Sriram D, Clercq E DE., Pannecouque C and Witvrouw M, *Indian J. Pharm. Sci.*, 1998, **60(4)**, 207-212.
34. Fleischman S H and Brooks C L, *Proteins: Structure, Function and Genetics*, 1990, **7**, 52-61.
35. Suling W J, Reynolds R C, Barrow E W, Wilson L N, Piper J R and Barrow W W, *Journal of Antimicrobial Chemotherapy*, 1998, **42**, 811-815.
36. Gulcan M, Sonmez M and Berber I, *Turkey Journal of Chemistry*, 2012, **36(1)**, 189-200.
37. Raman N, Kulandaisamy A and Jeyasubramanian K, *Synth. React. Inorg. Met. -Org. Chem.*, 2001, **31(7)**, 1249-1270.
38. Wynne K J and Pearson P S, *Inorg. Chem.*, 1971, **10**, 2735-2739.
39. Wynne K J and Pearson P S, *J. Chem. Soc. Commun.*, 1970, 556.
40. Wynne K J, Clark A J and Berg M, *J. Chem. Soc. Dalton*, 1972, 2370-2374.
41. Clark E R, Collet A J and Naik D G, *J. Chem. Soc. Dalton*, 1973, 1961-1962.
42. Berg M C, *Diss. Abstr. Int.*, 1972, **33**, 2982.
43. Srivastava T N, Singh M and Singh H B, *Indian J. Chem.*, 1982, **21A**, 307-309.
44. Srivastava T N, Srivastava R C and Srivastava M, *Indian J. Chem.*, 1982, **21A**, 539.
45. Srivastava T N, Srivastava R C and Srivastava V K, *J. Indian Chem. Soc.*, 1983, **60**, 891-892.



46. Garad M V, *Polyhedron*, 1985, **4**, 1353-1355.
47. Verma K K and Reena, *Synth. React. Inorg. Met. –Org. Chem.*, 1999, **29**, 499-512.
48. Verma K K, Dahiya R and Soni D, *Synth. React. Inorg. Met. – Org. Chem.*, 1999, **29**, 1033-1052.
49. Verma K K and Dahiya R, *Synth. React. Inorg. Met. –Org. Chem.*, 1999, **29**, 1299-1314.
50. Verma K K and Reena, *Phosphorus, Sulfur and Silicon and the Related Elements*, 1999, **148**, 2127-2134.
51. Verma K K and Seema, *Int. J. Chem. Sci.*, 2008, **6**, 371-380.
52. Srivastava S, Soni D K and Gupta H S, *J. Indian Chem. Soc.*, 1996, **73**, 255.
53. Narwal J K, Chhabra S, Malik R K, Garg S and Verma K K, *Oriental J. Chem.*, 2013, **29**, 1339-1349.
54. Chhabra S and Verma K K, *J. Chem. Pharm. Res.*, 2010, **2**, 569-575.
55. Vogel A I, *A Test Book of Organic Chemistry*, 3rd Edn., Longman, London, 1975.
56. Weissberger A, Ed., *Technique of Organic Chemistry*, Vol. 7, 2nd Edn., Interscience Publishers, Inc. N. Y., 1967.
57. Morgan G T and Kellet R E, *J. Chem. Soc.*, 1926, 1080-1088.
58. Petragnani N and Stefani H A, *Tellurium in Organic Chemistry*, 2nd Edn., Academic Press, London, 2007, 67, 76.
59. Bergman J, *Tetrahedron*, 1972, **28**, 3323-3331.
60. Khandelwal B L, Kumar K and Berry F J, *Inorg. Chim. Acta*, 1981, **99**, 135-137.
61. Berry F J, Kustan E H, Roshani M and Smith B C, *J. Organometal. Chem.*, 1975, **99**, 115-117.
62. Khandelwal B L, Kumar K and Raina K, *Synth. React. Inorg.*

- Met. –Org. Chem.*, 1981, **11**, 65-78.
63. Geary W J, *Coord. Chem. Rev.*, 1971, **7**, 81-122.
64. Greenwood N N, Straughan B P and Wilson A E, *J. Chem. Soc. A*, 1968, 2209-2212.
65. Srivastava K P, Singh A and Singh S K, *IOSR J. Appl. Chem.*, 2014, **7(4)**, 16-23.
66. Baker A W and Shulgin A T, *J. Am. Chem. Soc.*, 1959, **81**, 1523.
67. Freedman H H, *J. Am. Chem. Soc.*, 1961, **83**, 2900-2905.
68. Flett M St C, *Spectrochim. Acta.*, 1957, **10**, 21-37.
69. Bellamy I J, *Infrared Spectra of Complex Molecules*, Chapman and Hall Ltd. London, 1975.
70. Matijević-Sosa J, Vinković M and Vikić-Topić D, *Croatica Chemica Acta.*, 2006, **79(3)**, 489-495.
71. Mishra A P and Soni M, *Metal Based Drugs*, 2008, **71**, 243. DOI:10.1155/2008/875410.
72. Aminabhavi T M, Biradar N S and Patil C S, *Inorganica Chimica Acta.*, 1983, **78**, 107-111.
73. Biradar N S, Aminabhavi T M and Patil C S, *Inorganica Chimica Acta.*, 1983, **78**, 47-50.
74. Tumer M, Celik C, Koksall H and Serin S, *Transition Metal Chemistry*, 1999, **24**, 525-532.
75. Gwaram N S, Mohd Ali H, Khaledi H, Abdulla M A, Hamid A, Hadi A, Kawi Lin T, Ching C L and Ooi C L, *molecules*, 2012, **17**, 5952.
76. Rudzinski W E and Aminabhavi T M, *Inorganica Chimica Acta.*, 1982, **67**, 177-182.
77. Osowole A A, Wakil S M and Alao O K, *World Applied Sciences Journal*, 2015, **33(2)**, 336-342.
78. UR-Rehman S, Faiz A and Nawaz R, *J. Chil. Chem. Soc.*, 2013, **58(1)**, 1624-1627.
79. Mohamed G G and Abd El-Wahab Z H, *Journal of Thermal*



- Analysis and Calorimetry*, 2003, **73**, 347-359.
80. Verma K K, Soni D and verma, *Phosphorus, sulfur and silicon*, 2000, **166**, 231-241.
81. Pant B C, McWhinnie W R and Dance N S, *J. Organometal. Chem.*, 1973, **63**, 305-310.
82. Srivastava T N, Singh J D, *Indian J. Chem.*, 1987, **26A**, 260.
83. Chauhan S, Garg S and Verma K K, *Chem. Sci. Trans.*, 2016, **5(2)**, 431-441.
84. Kulkarani YD, Srivastava S, Abdi SHR and Athar M, *Synth. React. Inorg. Met. –Org. Chem.*, 1985, **15(8)**, 1043.
85. Chauhan S, Garg S and Verma K K, *Res. J. Pharm. Biol. Chem. Sci.*, 2016, **7(2)**, 265-274.
86. Aminabhavi T M and Rudzinski W E, *Inorganica Chimica Acta.*, 1983, **78**, L131- L134.
87. Aminabhavi T M and Rudzinski W E, *Inorganica Chimica Acta.*, 1983, **78**, 51-60.
88. Cappuccino J C, Sherman N, *Microbiology- A Laboratory Manual, Addison Wesley, California*, 1999, 263.
89. Pharmacopoeia of India, Volume 1, *Controller of Publications*, Ministry of Health Department, Government of India, New Delhi, 2007, 37.